HC Wainwright Predicts IN8bio’s Q1 Earnings (NASDAQ:INAB)

IN8bio, Inc. (NASDAQ:INAB) – Analysts at HC Wainwright issued their Q1 2026 EPS estimates for IN8bio in a research note issued on Thursday, May 8th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.04) for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for IN8bio’s Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at ($0.05) EPS and Q4 2026 earnings at ($0.05) EPS.

IN8bio Stock Down 6.3 %

IN8bio stock opened at $0.16 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.84 and a current ratio of 1.84. IN8bio has a one year low of $0.13 and a one year high of $1.74. The company has a 50-day simple moving average of $0.19 and a 200-day simple moving average of $0.26. The firm has a market capitalization of $12.79 million, a P/E ratio of -0.21 and a beta of 0.23.

IN8bio (NASDAQ:INAB) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01).

Institutional Investors Weigh In On IN8bio

A number of hedge funds have recently made changes to their positions in the business. Jane Street Group LLC increased its position in IN8bio by 296.7% in the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock valued at $30,000 after acquiring an additional 86,696 shares during the period. Geode Capital Management LLC grew its stake in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after purchasing an additional 185,919 shares in the last quarter. Sigma Planning Corp grew its stake in shares of IN8bio by 22.3% in the fourth quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock worth $268,000 after purchasing an additional 190,100 shares in the last quarter. Alyeska Investment Group L.P. raised its stake in shares of IN8bio by 1,064.5% during the fourth quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock valued at $1,302,000 after purchasing an additional 4,628,482 shares in the last quarter. Finally, Franklin Resources Inc. acquired a new stake in IN8bio in the fourth quarter worth about $1,465,000. Institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.